Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (101-110 of 357) with videos related to

Pageof 36
Sort By:
Drug Safety|January 17, 2019
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung CancerDanilo Rocco, Ciro Battiloro, Luigi Della Gravara, et al.
Reviews on Recent Clinical Trials|December 7, 2018
Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and BeyondDanilo Rocco, Ciro Battiloro, Luigi Della Gravara, et al.
Cancer Drug Resistance (Alhambra, Calif.)|January 11, 2023
The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome themDanilo Rocco, Luigi Della Gravara, Giovanni Palazzolo, et al.
Expert Opinion on Biological Therapy|December 23, 2020
The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung CancerDanilo Rocco, Luigi Della Gravara, Ciro Battiloro, et al.
Current Medicinal Chemistry|August 3, 2023
The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping MutationDanilo Rocco, Luigi Della Gravara, Giovanni Palazzolo, et al.
Expert Opinion on Biological Therapy|September 5, 2025
Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodiesDanilo Rocco, Luigi Della Gravara, Cristina Boccia, et al.
The Oncologist|October 27, 2007
The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developmentsCesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Expert Review of Respiratory Medicine|August 11, 2018
Treatment of advanced non-small cell lung cancer in the elderlyPaola C Sacco, Paolo Maione, Giovanni Palazzolo, et al.
Nature Clinical Practice. Oncology|March 8, 2006
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?Massimo Di Maio, Cesare Gridelli, Ciro Gallo, et al.
Current Clinical Pharmacology|December 3, 2016
The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung CancerPaola C Sacco, Paolo Maione, Cesare Guida, et al.
Pageof 36

Showing results (101-110 of 357) with videos related to

Sort By:
Pageof 36
Drug Safety|January 17, 2019
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung CancerDanilo Rocco, Ciro Battiloro, Luigi Della Gravara, et al.
Reviews on Recent Clinical Trials|December 7, 2018
Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and BeyondDanilo Rocco, Ciro Battiloro, Luigi Della Gravara, et al.
Cancer Drug Resistance (Alhambra, Calif.)|January 11, 2023
The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome themDanilo Rocco, Luigi Della Gravara, Giovanni Palazzolo, et al.
Expert Opinion on Biological Therapy|December 23, 2020
The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung CancerDanilo Rocco, Luigi Della Gravara, Ciro Battiloro, et al.
Current Medicinal Chemistry|August 3, 2023
The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping MutationDanilo Rocco, Luigi Della Gravara, Giovanni Palazzolo, et al.
Expert Opinion on Biological Therapy|September 5, 2025
Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodiesDanilo Rocco, Luigi Della Gravara, Cristina Boccia, et al.
The Oncologist|October 27, 2007
The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developmentsCesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Expert Review of Respiratory Medicine|August 11, 2018
Treatment of advanced non-small cell lung cancer in the elderlyPaola C Sacco, Paolo Maione, Giovanni Palazzolo, et al.
Nature Clinical Practice. Oncology|March 8, 2006
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?Massimo Di Maio, Cesare Gridelli, Ciro Gallo, et al.
Current Clinical Pharmacology|December 3, 2016
The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung CancerPaola C Sacco, Paolo Maione, Cesare Guida, et al.
Pageof 36